Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.

Oncotarget · 2015 · PMC4747358 · PMID 26510912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A recent Phase II study of sorafenib and everolimus represents the first positive study for relapsed osteosarcoma in decades, but even this study did not reach statistical significance for the primary outcome [ 3 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.